Noxopharm Limited is a drug development company. The Company is engaged in the research and development of NOX66 in the field of adjuvant therapy in chemotherapy and radiotherapy. The Company focuses on developing a drug to treat cancer. The Company has a primary focus on the development of drugs to treat the problem of drug- and radio-resistance in cancer cells. The Company's drug NOX66 is a dosage formulation developed to protect idronoxil from being inactivated in the human body by Phase II metabolism. Its purpose is to ensure that idronoxil administered remains in an active form. The Company has its offices in Melbourne and Sydney.